Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Julian Hercun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency, Liver Cirrhosis, Hypertension, Portal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the most common findings. Nonetheless, the evolution of liver disease over time remains unknown.
Methods
Retrospective review of patients followed at the National Institutes of Health with CVID‐related liver disease and liver biopsy from 1990 to 2020. Clinical, imaging and histological follow‐up were recorded as part of clinical research protocols.
Results
Forty patients were included, with a median age of 37.5 years at initial biopsy, 73% presenting with clear evidence of NRH, and a median fibrosis stage of 1. At biopsy, median platelet count was 100 × 10 9 /L, spleen size 19.5 cm, hepatic venous pressure gradient 9.5 mmHg and 37.5% of patients had signs of PH. Cumulative incidence of PH was 65% at 5 years. In a subgroup of 16 patients, a follow‐up liver biopsy, performed at a median time of 3 years after the index biopsy, revealed an increase in fibrosis by ≥2 stages in 31% of cases and an increase to an overall stage of 2.2 ( p = 0.001). No clinical or histological factors were associated with progression of fibrosis.
Conclusions
In this CVID cohort, NRH is the most common initial histological finding; however, unexpectedly fibrosis progresses over time in a subgroup of patients. A better understanding of the underlying causal process of liver disease CVID might lead to improved outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Julian Hercun, Anusha Vittal, Christopher Koh
Zitieren
APA
Hercun, J., Asif, B., Vittal, A., Ahmed, A., Gopalakrishna Pillai, H. K., Bergerson, J. R. E., Holland, S., Uzel, G., Strober, W., Fuss, I. J., Koh, C., Kleiner, D. E., & Heller, T. (2024). Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18180
Vancouver
Hercun J, Asif B, Vittal A, Ahmed A, Gopalakrishna Pillai HK, Bergerson JRE, et al. Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18180
BibTeX
@article{Hercun2024,
author = {Hercun, Julian and Asif, Bilal and Vittal, Anusha and Ahmed, Abdel and Gopalakrishna Pillai, Harish Kumar and Bergerson, Jenna R E and Holland, Steven and Uzel, Gulbu and Strober, Warren and Fuss, Ivan J and Koh, Christopher and Kleiner, David E and Heller, Theo},
title = {Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18180}
}
EUVIMED